nature.com webcasts 
Part of a series of webcasts from PerkinElmer
Molecular imaging reveals ONC201 antitumor efficacy and immune stimulation in cancer models
Date: Wednesday, August 15, 2018
Time: 8AM PDT | 11AM EDT | 4PM BST | 5PM CEST
This webcast has been produced on behalf of the sponsor who retains sole responsibility for content.
About this content
About this webcast
ONC201 is a novel small molecule which is in clinical trials for both solid and hematopoietic malignancies.
To maximize the observed clinical benefits of ONC201 and further elucidate its mechanism of action, preclinical studies were developed to test the hypothesis that dose intensification of ONC201 may impact antitumor efficacy, inhibit metastasis, and promote an intra-tumoral immune response (cfr. Wagner et al. 2018 JCI). To properly investigate this hypothesis, multiple mouse models were used in conjunction with various in vivo imaging techniques including: microCT imaging to monitor tumour-burden within the lungs, MRI, and bioluminescence and fluorescence imaging using the IVIS® platform to track subcutaneous, orthotopic and metastatic tumor growth.
To further elucidate the immune-stimulatory and anti-metastatic potency of ONC201, confocoal microscopy of 2D co-culture in established human NK and tumor cells using Vectra® Automated Quantitative pathology imaging and Inform® Software of IHC xenograft sections were performed.
During this webcast, the speakers will address the benefits of cell culture, xenograft tissue sections and mouse models coupled with imaging in preclinical immuno-oncology trials.
Unable to join the live event?
Watch on demand — register now to ensure that you receive information on how to gain access after the live event.
If you have already registered, we look forward to meeting you!
Speakers
 |
Dr. Harvey Hensley Research Associate Professor and Manager Fox Chase Cancer Center |
 |
Dr. Jessica Wagner Postdoctoral Fellow St Jude’s Children’s Research Hospital |
Watch live or on-demand